Abstract
Z-DNA, the alternative form of double-stranded DNA involved in a variety of nucleotide metabolism, is recognized and stabilized by specific Z-DNA binding proteins (ZBPs). Three ZBPs known in vertebrates --ADAR1, DAI and PKZ-- modulate innate immunity, particularly, the IFN-induced immune response. The E3L protein of vaccinia virus appears to compete with the host ZBP for Z-DNA binding, thereby suppressing the host immune system. ZBPs are, therefore, considered to be attractive therapeutic targets for infectious and immune diseases. Recent advances in computer-aided drug development combined with the high-resolution crystal and NMR structures of ZBPs have enabled us to discover novel candidates for ZBP inhibitors. In this study, we present an overview of Z-DNA and known ZBPs as drug targets, and summarize recent progress in the structure-based identification of ZBP inhibitors.
Keywords: Z-DNA, Z-DNA binding protein, ADAR1, DAI (DLM-1/ZBP1), PKZ, E3L, Zα domain, Zβ domain, computeraided drug design, virtual screening
Current Drug Targets
Title: Z-DNA Binding Proteins as Targets for Structure-Based Virtual Screening
Volume: 11 Issue: 3
Author(s): Doyoun Kim, Young -Ho Lee, Hye-Yeon Hwang, Kyeong Kyu Kim and Hyun-Ju Park
Affiliation:
Keywords: Z-DNA, Z-DNA binding protein, ADAR1, DAI (DLM-1/ZBP1), PKZ, E3L, Zα domain, Zβ domain, computeraided drug design, virtual screening
Abstract: Z-DNA, the alternative form of double-stranded DNA involved in a variety of nucleotide metabolism, is recognized and stabilized by specific Z-DNA binding proteins (ZBPs). Three ZBPs known in vertebrates --ADAR1, DAI and PKZ-- modulate innate immunity, particularly, the IFN-induced immune response. The E3L protein of vaccinia virus appears to compete with the host ZBP for Z-DNA binding, thereby suppressing the host immune system. ZBPs are, therefore, considered to be attractive therapeutic targets for infectious and immune diseases. Recent advances in computer-aided drug development combined with the high-resolution crystal and NMR structures of ZBPs have enabled us to discover novel candidates for ZBP inhibitors. In this study, we present an overview of Z-DNA and known ZBPs as drug targets, and summarize recent progress in the structure-based identification of ZBP inhibitors.
Export Options
About this article
Cite this article as:
Kim Doyoun, Lee Young -Ho, Hwang Hye-Yeon, Kim Kyu Kyeong and Park Hyun-Ju, Z-DNA Binding Proteins as Targets for Structure-Based Virtual Screening, Current Drug Targets 2010; 11 (3) . https://dx.doi.org/10.2174/138945010790711905
DOI https://dx.doi.org/10.2174/138945010790711905 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma
Current Signal Transduction Therapy Auraptene: A Natural Biologically Active Compound with Multiple Targets
Current Drug Targets A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Editorial from Editor-in-Chief
Current Medical Imaging GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Alpinia officinarum
Mini-Reviews in Medicinal Chemistry The Role of 5-Hydroxymethylcytosine in Aging and Alzheimer’s Disease: Current Status and Prospects for Future Studies
Current Alzheimer Research Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin
Current Drug Targets RNA Base Damage and Repair
Current Pharmaceutical Biotechnology Chemotherapy for Prostate Cancer
Current Pharmaceutical Design Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design A Century of Thioxanthones: Through Synthesis and Biological Applications
Current Medicinal Chemistry Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach
Current Respiratory Medicine Reviews 3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors
Letters in Drug Design & Discovery Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Current Drug Targets Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design